The Honest Dose #20

A fair amount of the education-first content I have been putting out lately has been getting pulled down, TikTok mostly. Not the sales and vendor content I’m sure you’ve all seen , but mine. The content whose entire purpose is to say what a compound is, what the research actually shows, and where the claims outrun the evidence, with nothing to buy at the end of it.

What I keep turning over is the mechanism behind that. The takedowns are downstream of exactly the kind of thing this issue is about, federal pressure on the peptide market working its way, filter by filter, into what survives on a feed. I am not against that pressure in principle. The internet is drowning in health misinformation, and peptides are not an exception to that, they are one of its sharper edges. Some enforcement here is warranted.

The part that stings is the shape it takes at the platform level. Speak plainly and factually, with no product and no incentive, and you are easy to catch, because you are using the real words. Meanwhile the accounts calling peptides "peppers," or a compound "ratatouille," or shrinking retatrutide down to a lone "r" to slip the filters, tend to stay up, and those are often the accounts actively selling into the opacity of the gray market and profiting from it. The honest signal gets flagged for using real language while the evasive sales pitch keeps its reach.

So it is both frustrating and equally fascinating. It is not a deterrent. It is just a thing I have watched happen in real time and will have to stay cognizant of as this grows. Which makes this a fitting week to look at the machinery itself.

Let's get into it.

On September 1 the FDA made public a batch of warning letters, all dated August 24, from its drug-evaluation center to five online peptide vendors. The companies are Peak Performance Peptides, Royal Peptides, NuScience Peptides, Peptide Partners, and TXP Innovations doing business as Tex Peptides. Each has fifteen business days to respond. On its face this is another entry in a long enforcement year. Underneath, it is one of the cleaner statements the agency has put on paper about how it now reads this market, and it is worth walking through.

What actually happened. The agency reviewed each company's website in July, pulled the marketing language off the pages, and concluded the products are drugs. Not because of what was in the vials, but because of what the sites said the vials would do. The letters name a long roster across the five companies: the familiar GLP names Semaglutide, Tirzepatide, and Retatrutide, the newer Survodutide and Mazdutide, and then the boutique shelf everyone in this space actually cares about, SS-31, PT-141, Tesamorelin, Ipamorelin blends, and in one case Bimorelin. Alongside them, bacteriostatic water.

The legal move that matters. Every one of these products carried some version of "research use only" or "not for human consumption." The agency's position, stated in nearly identical language across the letters, is that the disclaimer does not survive contact with the rest of the page. Once a site explains what a compound does to appetite, glucose, libido, mitochondria, or muscle, it has established intended use, and a capitalized "NOT FOR HUMAN USE" at the bottom does not undo that. In the letters' own words, the evidence from the website establishes that the products are "intended to be drugs for human use." That is the sentence that ends the research-use-only era as a legal strategy. It was never a shield. It just had not been tested this plainly in writing until now.

The bacteriostatic water twist. In several letters the agency went after the sterile water sold for reconstitution and called it a drug too, on the logic that selling reconstitution fluid next to injectable peptides that require reconstitution demonstrates a combined intended use. In the NuScience letter, an on-site "peptide calculator" that walks a buyer through preparing an injection was cited as part of the same picture. The water is inert. The context around it is what got named. That is the agency telling you it is reading the whole storefront, not the product label in isolation.

Where this sits in the campaign. These five did not come out of nowhere. The pattern this year has been methodical, one link in the supply chain at a time. Telehealth marketers drew letters earlier in the year, the 503A compounding framework is being tightened through rulemaking, an earlier vendor batch went out on March 31, and now the direct-to-consumer online sellers are getting their turn. Read together, it is less a crackdown than a survey, the agency demonstrating a different enforcement tool for each segment of the market and leaving a paper trail of how it justifies each one.

The part to consider closely. Look again at that compound roster, because it is doing something the "unapproved new drug" framing hides. Three of the names on it are approved drugs. Tesamorelin is Egrifta, approved back in 2010. PT-141 is Bremelanotide, sold as Vyleesi since 2019. SS-31 is Elamipretide, which the FDA granted accelerated approval in September 2025 as the first mitochondria-targeted therapy, for an ultra-rare condition. So "unapproved new drug" here does not mean the molecule is unstudied or has never passed the agency's bar. It is a precise statement that this seller has no approved application for the use they are marketing. The molecule's resume and the vendor's legal standing are two different things, and the letter is only about the second one. That gap is exactly where the RQS lives, so it is where the spotlight goes.

Track the enforcement timeline on the regulatory page

The claim: Digestion runs on stomach acid, and it is that acidic for a reason. Pour a big glass of water on top of a meal and you thin the acid out, weaken the enzymes, and food moves through half-broken-down. So keep fluids away from food, drink thirty minutes before or after, and let the acid work at full strength. The logic is clean and mechanical, which is exactly why it has traveled through wellness content for a century.

The reality: The mechanism sounds airtight on a whiteboard, but it falls apart the moment you remember the stomach is not a static beaker of acid you can water down. It is a regulated organ that makes acid on demand. Parietal cells secrete hydrochloric acid continuously in response to a meal, and if the contents get diluted, secretion ramps to match. Acid is not a fixed pour you spend and thin out. It’s more like a thermostat.

The single study people reach for actually undercuts the claim. In twelve participants, water raised stomach pH briefly, for about three minutes, and the body corrected it. But they were fasting, not eating, and food is the specific signal that tells the stomach to produce acid. So the one experiment cited as proof measured the scenario the claim is not even about, and still showed the system self-correcting in minutes.

Then the sense of scale is simply wrong. Food buffers stomach acid far more than a glass of water does, pushing pH up into the 4-to-5 range during a normal meal, and the stomach handles that routinely by making more acid. Against the buffering load of the food itself, a glass of water is a rounding error. And if diluting gastric contents actually broke digestion, then soup, broth, smoothies, and watery vegetables, which are mostly water, would be nutritional disasters. They are not. A bowl of soup is more dilution than a glass of water, and nobody warns you off soup.

There is a tell in who gets the warning. The rule almost never gets applied to soda, juice, or wine with dinner, only to water, which is the one beverage in that list with nothing wrong with it. Of the others, alcohol is the one that genuinely does interfere with digestion, slowing gastric emptying and impairing absorption. The folklore lands its caution on the harmless drink and waves through the ones with real effects.

Where the claim has a narrow, real kernel, because it does. For some people, moderating fluid volume at meals is reasonable, just not for the reason given. It is about volume and mechanics, not acid strength. People with reflux can find that a large drink raises abdominal pressure and worsens symptoms. People with slow gastric emptying, from gastroparesis, some diabetes, post-bariatric anatomy, or simply age, may feel uncomfortably full if they gulp a lot of liquid with food, so sipping beats chugging. And low stomach acid, hypochlorhydria, is real in older adults, long-term acid-suppressant users, and atrophic gastritis, but that is a medical condition, not something a glass of water causes, and the fix is not avoiding water at dinner. The honest residue is small and specific, and it is a comfort adjustment for particular bodies, not a universal law.

The honest version of the claim: For a healthy person, drinking water with a meal does nothing bad to digestion. The stomach makes acid to match what is in it and treats your water as trivial next to the food. The part worth keeping is much smaller and differently labeled: if you have reflux, slow emptying, or you feel full early, large volumes of any liquid can be uncomfortable, so sip rather than chug. It is the same lesson the lead was teaching in a different key. The label on the front, whether it is "research use only" or "acid plus water weakens digestion," does not get to overrule what the thing actually is and actually does. The reality underneath does not care what the front of the package says.

I want to put two compounds from the enforcement roster side by side, SS-31 and Ipamorelin, because the warning letter treats them identically and the RQS does not.

SS-31 sits at 50. Ipamorelin sits at 35. On the seller's page they are neighbors on the same shelf, and in the FDA letter they are the same kind of violation, unapproved new drugs marketed with body-function claims. By research quality they are not close. SS-31, as Elamipretide, carried a molecule through a clinical trial program to an accelerated FDA approval, even if that pivotal was a small, open-label study resting on a surrogate endpoint, which is a real limitation the score should reflect and not a footnote to wave away. Ipamorelin has never been approved for anything and its human record is thinner and shorter. Same shelf, same letter, different evidentiary depth.

Here is the discipline the spotlight is really about this week. The RQS grades the research on the molecule. The FDA letter grades the seller's conduct. Neither one grades what is in the vendor's vial. A compound can have a genuine trial record and a brand-name approval, and the gray-market version of it can still be an unverified product from a seller who just got a federal letter for how they market it. Those are three separate questions, research quality, regulatory standing, and product reality, and the whole reason to keep them separate is that the market blends them on purpose. A molecule with real science becomes marketing cover for a vial with none. The RQS answers exactly one of the three, and says so. It is not a safety rating, not an efficacy rating, and not a statement that any particular vial is what its label claims.

Compare the roster compounds on the compare page

Watch the fifteen-business-day clock, because a warning letter is a first move, not a last one.
Each of the five vendors has a short window to respond, and it is worth being clear on what the letter is and is not. It is not a fine, a ban, or a finding of guilt. It is the agency putting a documented position on the record and giving the company a chance to fix it. What matters is what comes next if they do not, since the escalation ladder from here runs through seizures, injunctions, and referrals. The value of this batch is less the immediate consequence than the template it sets, a reusable legal argument the agency can now point at any storefront that looks the same.

Retatrutide is on this list and on the approval track at the same time.
One of the GLP names cited across the letters, retatrutide, is simultaneously moving through the legitimate pipeline, with positive late stage readouts reported over the summer and an NDA filing targeted for early 2027. It is a preview of the whole arc. The same compound can be a gray-market research chemical and an about-to-be-approved drug in the same news cycle, and once approval lands, the gray-market version does not vanish, it gets squeezed between an approved product and a sharper enforcement posture. We watched exactly that play out with semaglutide and tirzepatide. Retatrutide is next in line for the same treatment.

Federal enforcement is tightening while at least one state is opening a door.
Set the August sweep against Louisiana's SB 253, which took effect August 1 as the first state peptide access statute in the country. The two are pointed in opposite directions, a federal agency narrowing what sellers can say while a state builds a lane for access. That tension is the thing to track heading into 2027, because it decides whether this market gets pushed underground, pulled into a regulated channel, or split messily across state lines. Which of those wins is still genuinely open.

Hopefully that was helpful/interesting, see you next week.

-Emeka

Peptidclear.com

You're receiving this because you signed up at peptideclear.com. No sponsors. No affiliate links. Just the research, translated.